SET/TAF-I Antikörper

Produktnummer ABIN4620361

Produktdetails anti-SET/TAF-I Antikörper

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SET/TAF-I Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Spezifität: This antibody detects I2PP2A / SET, widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.

Aufreinigung: Affinity chromatography

Immunogen: Synthetic peptide derived from the human SET protein

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot (1: 400 dilution).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate buffered saline with 0.08 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store the product (in aliquots) at -20 °C to -70 °C. Can be shipped at 2 - 8 °C.

Referenzen für anti-SET/TAF-I Antikörper (ABIN4620361)

Shih, Shih, Lee, Huang, Wang, Chen, Tsai: "Particle size distributions and health-related exposures of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) of sinter plant workers." in: Chemosphere, (2009) (PubMed).

Details zu SET/TAF-I

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Andere Bezeichnung: SET / I2PP2A (SET Produkte)

Synonyme: 2PP2A antikoerper, I2PP2A antikoerper, IGAAD antikoerper, IPP2A2 antikoerper, PHAPII antikoerper, TAF-I antikoerper, TAF-IBETA antikoerper, 2610030F17Rik antikoerper, 5730420M11Rik antikoerper, AA407739 antikoerper, I-2PP2A antikoerper, StF-IT-1 antikoerper, 2pp2a antikoerper, i2pp2a antikoerper, igaad antikoerper, ipp2a2 antikoerper, phapii antikoerper, set antikoerper, set-a antikoerper, set-b antikoerper, taf-ibeta antikoerper, wu:fb30g11 antikoerper, wu:fd16c08 antikoerper, SET nuclear proto-oncogene antikoerper, SET nuclear oncogene antikoerper, SET translocation antikoerper, SET nuclear proto-oncogene L homeolog antikoerper, SET nuclear proto-oncogene b antikoerper, SET antikoerper, Set antikoerper, LOC403555 antikoerper, set.L antikoerper, setb antikoerper

Hintergrund: Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.Synonyms: I-2PP2A, IGAAD, Inhibitor of granzyme A-activated DNase, PHAPII, Phosphatase 2A inhibitor I2PP2A, TAF-I, Template-activating factor I

Gen-ID: 6418

NCBI Accession: NP_001116293

UniProt: H0UI37

Pathways: Apoptose